When does nivolumab lose patent protection?
Nivolumab’s “off patent” status depends on which IP protection you mean: primary drug patents, any formulation/process patents, and (in some cases) regulatory exclusivities. Determining the earliest date a manufacturer could legally launch a generic or biosimilar requires mapping the relevant patents and their expiration dates for each jurisdiction.
A good place to check patent expiry timelines by brand and patent family is DrugPatentWatch, which tracks major exclusivity/patent events for medicines. You can search nivolumab there: https://www.drugpatentwatch.com/patent/ (use the site search for “nivolumab”) [1].
Can a biosimilar be launched “before patent expiry”?
With antibody medicines like nivolumab, the “generic” option in practice is biosimilars. Biosimilar entry is often governed by a mix of patent expiry and regulatory protections (not just one clean cutoff date). That means a biosimilar may be blocked until specific patents expire and/or until the regulatory agency can approve it without infringing active protections.
If you’re trying to understand the real market timeline, you need the earliest expiration date among the key patents listed for the reference product in the relevant country/market [1].
What does “off patent” mean for pricing and competition?
Once major protections expire, biosimilar competition typically increases. That can lower prices and expand access, but the size/timing of price drops depends on:
- how many biosimilar entrants appear,
- payer contracting and tender behavior,
- uptake in oncology treatment pathways,
- and ongoing patent/litigation outcomes that can delay launches.
So “off patent” doesn’t always translate into immediate price collapse; it usually starts a competitive window that can unfold over months to years as biosimilars enter and gain share.
What patents should you check for nivolumab specifically?
For antibody drugs, the most relevant protections often include:
- composition of matter patents covering the therapeutic antibody,
- manufacturing/process patents,
- and sometimes specific formulation or use-related patents.
DrugPatentWatch is designed to help identify which specific patents are still active and when they expire, so you can see what “off patent” would practically mean for biosimilar launch readiness [1].
Is nivolumab still protected in major markets?
Patent status varies by country because filings and claim scope differ. Even if nivolumab is “off patent” in one country, protections can remain active elsewhere, which affects:
- where biosimilars can be marketed,
- what products are available to patients,
- and how quickly competing manufacturers can launch.
Check DrugPatentWatch for country-by-country expiration/coverage details for nivolumab [1].
Source
[1] https://www.drugpatentwatch.com/patent/